Keyphrases
Recombinant interleukin-2
100%
Lymphokine-activated Killer Cells
100%
Hepatic Metastasis
100%
Liver Metastasis
45%
Percentage Reduction
45%
Metastasis
27%
Splenocytes
18%
Pulmonary Metastasis
18%
Treatment Effect
9%
Interleukin-2
9%
Murine Model
9%
Escherichia Coli
9%
Tumor Cells
9%
In(III)
9%
Incubation
9%
Means of Control
9%
Total Body Irradiation
9%
Therapeutic Effect
9%
Effective Therapy
9%
Metastatic Cancer
9%
Systemic Injection
9%
Sublethal
9%
Micrometastasis
9%
Mouse Splenocytes
9%
Mean Reduction
9%
Intrasplenic Injection
9%
Medicine and Dentistry
Immunotherapy
100%
Lymphokine Activated Killer Cell
100%
Recombinant Interleukin 2
100%
Experimental Liver Metastasis
100%
Liver Metastasis
63%
Metastatic Carcinoma
36%
Lung Metastasis
18%
Tumor Cell
9%
Interleukin 2
9%
In Vitro
9%
Escherichia coli
9%
Whole Body Radiation
9%
Therapy Effect
9%
Incubation
9%
Micrometastasis
9%
Intrasplenic Drug Administration
9%
Immunology and Microbiology
Immunotherapy
100%
Recombinant Interleukin 2
100%
Lymphokine Activated Killer Cell
100%
Mouse
27%
Splenocyte
27%
Interleukin 2
9%
Tumor Cell
9%
Escherichia coli
9%
Neuroscience
Immunotherapy
100%
Lymphokine
100%
Recombinant Interleukin 2
100%
Splenocyte
27%
In Vitro
9%
Interleukin 2
9%
Veterinary Science and Veterinary Medicine
Mouse
100%
Splenocyte
100%
Escherichia coli
33%
Nursing and Health Professions
Experimental Liver Metastasis
100%